Presentation and Status in Health Basket
Presentation | Basket | Yarpa | Pharmasoft |
---|---|---|---|
Tablets 30 x 25 mg |
9546 | 14081 | |
Tablets 30 x 50 mg |
8315 | 14359 | |
Tablets 30 x 100 mg |
8314 | 14360 |
Related information
Dosage
The dose must always be adjusted to individual requirements of the patients, with the lowest possible starting dosage.
The following guidelines:
Adults:
Angina: Initially 50mg once a day, the dosage being increased gradually to 100 mg after 1 week, as needed and tolerated.
Myocardial Infarction: For patients who present some days after suffering an acute myocardial infarction, an oral dose of Normalol 100 mg daily is recommended for long-term prophylaxis of myocardial infarction.
Hypertension: Initially 25-50 mg once a day, the dosage being increased gradually to 100 mg a day after two weeks, as needed and tolerated.
Older population: Dosage requirements may be reduced, especially in patients with impaired renal function.
Pediatric population: Due to the lack of experience in pediatric patients, atenolol is not recommended for use in children.
Renal failure: Since Atenolol is excreted via the kidneys, the dosage should be adjusted in cases of severe impairment of renal function.
No significant accumulation of Atenolol occurs in patients who have a creatinine clearance greater than 35 ml/min/1.73 m2 (normal range is 100–150 ml/min/1.73 m2).
For patients with a creatinine clearance of 15–35 ml/min/1.73 m2 (equivalent to serum creatinine of 300–600 micromol/litre), the oral dose should be 50 mg daily.
For patients with a creatinine clearance of less than 15 ml/min/1.73 m2 (equivalent to serum creatinine of greater than 600 micromol/litre), the oral dose should be 25 mg daily or 50 mg on alternate days.
Patients on haemodialysis should be given 50 mg orally after each dialysis; this should be done under hospital supervision as marked falls in blood pressure can occur.
Indications
Treatment of angina pectoris, acute myocardial infarction, hypertension.
Contra-Indications
Patients with:
Hypersensitivity to the active substance, or to any of the excipients.
Cardiogenic shock.
Uncontrolled Heart failure.
Sick sinus syndrome.
2nd or 3rd degree heart block.
Untreated phaeochromocytoma.
Metabolic acidosis.
Bradycardia (<45 bpm).
Hypotension.
Severe peripheral arterial circulatory disturbances.
Please refer to the license holder for further details.
Special Precautions
Please refer to the license holder for further details.
Side Effects
Please refer to the license holder for further details”.
Drug interactions
Please refer to the license holder for further details.
Pregnancy and Lactation
Please refer to the license holder for further details.
Overdose
Please refer to the license holder for further details.
Important notes
Please refer to the license holder for further details.